VRNA - Verona Pharma plc

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 15.47

Open

$ 15.37

Bid

$ 0.00 x 0

Ask

$ 15.48 x 100

Day's Range

$ 15.23 - $ 15.59

52 Week Range

$ 11.83 - $ 23.81

Volume

260,511

Average Volume

Market Cap

9.81B

Beta (5Y Monthly)

$ 1.33

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-29-2024	12-31-2023	10-K
2	11-02-2023	09-30-2023	10-Q
3	08-03-2023	06-30-2023	10-Q
4	05-09-2023	03-31-2023	10-Q
5	03-07-2023	12-31-2022	10-K
6	11-09-2022	09-30-2022	10-Q
7	08-09-2022	06-30-2022	10-Q
8	05-03-2022	03-31-2022	10-Q
9	03-03-2022	12-31-2021	10-K
10	11-09-2021	09-30-2021	10-Q
11	08-05-2021	06-30-2021	10-Q
12	04-29-2021	03-31-2021	10-Q
13	02-25-2021	12-31-2020	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Piper Sandler Maintains Overweight on Vero...
04/16/2024 11:48:53

Piper Sandler analyst Yasmeen Rahimi maintains Verona Pharma (NASDAQ:VRNA) with a Overweight and raises the price target fro...

HC Wainwright & Co. Reiterates Buy on Vero...
03/04/2024 12:09:38

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...

Wedbush Reiterates Outperform on Verona Ph...
03/01/2024 13:37:02

Wedbush analyst Liana Moussatos reiterates Verona Pharma (NASDAQ:VRNA) with a Outperform and maintains $33 price target.

Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

Verona Pharma Q4 EPS $(0.02), Flat YoY, Ca...
02/29/2024 07:04:24

Earnings Preview For Verona Pharma
02/28/2024 17:01:45

HC Wainwright & Co. Reiterates Buy on Vero...
01/22/2024 11:14:29

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...

Verona Pharma Secures Up To $400M In Finan...
01/02/2024 07:13:24

Under the terms of the debt facility, the Company drew $50 million at closing, and may draw, subject to certain conditions prec...

Verona Pharma's Promising COPD Treatment P...
12/29/2023 18:24:29

In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revea...

HC Wainwright & Co. Reiterates Buy on Vero...
12/29/2023 13:28:27

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...

why-rayzebio-shares-are-trading-higher-by-100-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why RayzeBio Shares Are Trading Higher By ...
12/26/2023 18:48:21

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acqui...

Earnings Scheduled For November 2, 2023
11/02/2023 08:56:34

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on...

Verona Pharma Q3 EPADS $(0.16) Beats $(0.2...
11/02/2023 07:21:22

Verona Pharma (NASDAQ:VRNA) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.28)...

Verona Pharma Will Present Additional Anal...
10/03/2023 07:04:46

HC Wainwright & Co. Reiterates Buy on Vero...
09/11/2023 10:23:18

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...

FDA Accepts To Review Verona Pharma's New ...
09/11/2023 06:35:02

Verona Pharma To Share Further Insights Fr...
09/06/2023 06:55:45

Expert Ratings for Verona Pharma
09/01/2023 15:00:40

Canaccord Genuity Reiterates Buy on Verona...
09/01/2023 14:40:57

Canaccord Genuity analyst Edward Nash reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $35 price target.

HC Wainwright & Co. Reiterates Buy on Vero...
08/04/2023 11:05:30

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...